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Inositol and inositol-containing compounds have signalling and regulatory roles in many 
cellular processes, suggesting that inositol imbalance may lead to wide-ranging changes in 
cellular functions. Indeed, changes in inositol-dependent signalling have been implicated in 
various diseases and cellular functions such as autophagy, and these changes have often 
been proposed as therapeutic targets. However, few studies have highlighted the links 
between inositol depletion and the downstream effects on inositol phosphates and 
phosphoinositides in disease states. For this research, many advances have employed simple 
model systems that include the social amoeba D. discoideum and the yeast S. cerevisiae, 
since these models enable a range of experimental approaches that are not possible in 
mammalian models. In this review, we discuss recent findings initiated in simple model 
systems and translated to higher model organisms where the effect of altered inositol, inositol 
phosphate and phosphoinositide levels impact on bipolar disorder, Alzheimer disease, 
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Sources of inositol 
Myo-inositol is a stereoisomer of inositol that has critical roles in eukaryotes as a structural 
constituent of both inositol phosphates that act as second messengers in intracellular 
signalling pathways and phosphoinositides that have important roles in lipid signalling, cell 
signalling and membrane trafficking (Figure 1). Myo-inositol is naturally most abundant in 
fruits, vegetables, grains and nuts (Clements and Darnell, 1980). Dietary inositol intake 
provides one of three means to maintain cellular inositol levels through the Na+–myo-inositol 
transporters (SMITs) and the H+–myo-inositol transporter (HMIT) (Calker and Belmaker, 
2000). In addition, inositol can be recycled in the phosphatidylinositol (PI) cycle from inositol 
phosphates, which include inositol 1,4,5-trisphosphate (InsP3) and inositol 1,4-bisphosphate 
(InsP2) and higher order inositol phosphates such as InsP4, InsP5 and InsP6 (Irvine and Schell, 
2001) (Figure 1). Inositol can also be obtained by de novo synthesis, in which glucose 6-
phosphate is converted to myo-inositol 3-phosphate by myo-inositol-3-phosphate synthase 
(INO1), followed by dephosphorylation to inositol by inositol monophosphatase (IMPase) 
(Loewus et al., 1980). The relative contribution of these mechanisms to inositol homeostasis 
is likely to vary between different cell types and tissues. In the brain, the expression of INO1 
is confined to the vasculature (Wong et al., 1987) and thus cortical neurons are likely to rely 
on extracellular uptake and recycling of inositol (Di Daniel et al., 2006). Indeed, HMIT is 
expressed in several brain regions, including neurons of the frontal cortex, and SMIT2 is widely 
expressed in brain (Di Daniel et al., 2006). In testis, on the contrary, INO1 is expressed in the 
epithelial cells of the seminiferous tubules rather than in the blood vessels (Wong et al., 1987) 
and thus these cells are likely to rely on synthesis or recycling of inositol. In mammals, plasma 
concentrations of inositol range from 25 to 100 µM while intracellular concentrations are 
several-fold higher than in the circulation and the highest concentration is found in the brain 
(Kollros et al., 1990). 
Regulation of inositol synthesis 
The inositol biosynthetic pathway has been highly conserved throughout evolution (Majumder 
et al., 2003) and is essential for viability in a variety of model organisms, including 
Saccharomyces cerevisiae, Dictyostelium discoideum, Arabidopsis thaliana and mice 
(Culbertson and Henry, 1975; Lester and Gross, 1959; Martin and Smith, 2005; Meng et al., 
2009; Ohnishi et al., 2014). Owing to the essential role of inositol in cell function, studying the 
regulation of inositol biosynthesis is difficult in humans and other complex organisms (Keith et 
al., 1977), thus much of our understanding of inositol metabolism is based on extensive 
research in the yeast S. cerevisiae (Bachhawat et al., 1995; Dean-Johnson and Henry, 1989; 
Ju et al., 2004; Lopes et al., 1993) and the amoeba D. discoideum (Adley et al., 2006; Chang 
et al., 2012; Fischbach et al., 2006; Frej et al., 2016; Williams et al., 1999, 2002; Xu et al., 
2007).  
Inositol metabolism is tightly regulated. At the transcriptional level, INO1 expression in S. 
cerevisiae is repressed by inositol and this occurs by the binding of the overproducer of inositol 
protein 1 (Opi1) to the Ino2/Ino4 transcription regulator complex at the upstream activation 
sequence in the INO1 promoter (UASINO1) (Greenberg and Lopes, 1996). When cells 
experience a reduction in inositol levels, the suppressor of choline sensitivity protein 2 (Scs2) 
sequesters Opi1 in the ER and this relieves the repression of the Ino2/Ino4 complex, which 
activates INO1 transcription (Felberbaum et al., 2012). INO1 transcription is also regulated by 
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sumoylation, which is a post-translational protein modification by highly conserved small 
ubiquitin-related modifier (SUMO) proteins (Wang and Dasso, 2009). Mutations in the two 
yeast SUMO proteases, ubiquitin-like specific protease 1 (ULP1) and ULP2, decrease INO1 
gene transcription, which causes impaired cell growth in the absence of inositol and leads to 
an accumulation of sumoylated Scs2 (Felberbaum et al., 2012). INO1 transcription is also 
tightly regulated by the presence of choline, INO1 protein levels and cellular stresses like the 
unfolded protein response (UPR) (Brickner and Walter, 2004; Konarzewska et al., 2012; 
Shetty and Lopes, 2010). 
At the translational level, the de novo biosynthesis of inositol is primarily regulated by INO1 
(Figure 1), which is encoded by the INO1 gene in yeast and the ISYNA1 gene in humans 
(Loewus et al., 1980). The activity of yeast INO1 is regulated by phosphorylation at five sites 
in the protein (Deranieh et al., 2013). INO1 protein extracted from rat brain is also 
phosphorylated (Parthasarathy et al., 2013), where three of the phosphosites identified in 
yeast INO1 (S184, S296, S374) are conserved in human INO1 (S177, S279, S357) and 
phosphorylation at these sites was demonstrated to regulate INO1 activity in both organisms 
(Deranieh et al., 2013). In D. discoideum, the enzyme has also been shown to contribute to a 
macromolecular complex (Frej et al., 2016), which provides a potential mechanism for 
regulation of its activity by sequestration (Randise-Hinchliff and Brickner, 2016). In this model, 
in addition to the established role for INO1 in de novo inositol production, the enzyme is also 
involved in cell growth, cell shape and metabolic regulation (Frej et al., 2016). 
The IMPase enzyme, which is encoded by the INM1 and INM2 genes in yeast and the IMPA1 
and IMPA2 genes in humans, also has an important role in maintaining intracellular levels of 
myo-inositol. These protein control the dephosphorylation of inositol monophosphate isomers 
to produce myo-inositol as the final step of recycling inositol 1,4,5-trisphosphate (InsP3) to 
produce inositol (Ferruz et al., 2016). By this mechanism, IMPase regulates inositol 
homeostasis via phosphoinositide recycling and de novo inositol biosynthesis from glucose 6-
phosphate (Figure 1). In yeast, IMPase expression increases in the presence of inositol, 
although inositol does not affect enzyme activity in vitro (Murray and Greenberg, 1997). The 
enzyme requires magnesium ions for activity and is inhibited by lithium, which is a drug that is 
used as a mood-stabilizing treatment (Ferruz et al., 2016). It is not known whether IMPase is 
post-translationally modified, however it is clear that the amino (N)-terminal region of the 
protein is important for its activity (Whiting et al., 1990). 
The metabolic effects of inositol depletion 
Inositol has a critical role as a precursor in the synthesis of phosphoinositides, which include 
phosphatidylinositol (PI) and its phosphorylated derivatives such as PIP, PIP2 and PIP3 
(Figure 1). Phosphoinositides comprise a phosphatidic acid (PA) backbone (glycerol linked to 
two fatty acid tails) that is linked to inositol via a phosphate group, with further 
phosphorylations occurring at positions three, four and five on the inositol ring. 
Phosphoinositides reside in the inner leaflet of the plasma membrane and their levels are 
maintained at steady state by phosphorylation and dephosphorylation reactions that are 
performed by specific kinases and phosphatases and by phospholipase C dependent 
breakdown (Kurnasov et al., 2013). Controlled synthesis of the different phosphoinositides can 
occur in diverse intracellular compartments for distinct and independently regulated functions 
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with differing target enzymes. Phosphoinositides take part in a wide variety of cellular functions 
including motility and intracellular membrane trafficking (Cremona and De Camilli, 2001). 
Inositol phosphates are the second major class of molecules derived from inositol (Figure 1) 
and originate from the cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) by 
phospholipase C (PLC) to produce inositol 1,4,5-trisphosphate (InsP3) (Ferruz et al., 2016). 
InsP3 has a central role in triggering the release of intracellular calcium, but it can also be 
phosphorylated to form higher order phospholipids like inositol phosphates (InsP4, InsP5, 
InsP6) or inositol pyrophosphates (InsP7 and InsP8) (Pattni and Banting, 2004) that are 
involved in the regulation of gene expression and in protein post-translational modifications 
(Steger et al., 2003). These molecules are critically important for a range of cellular functions, 
including phospholipid synthesis, the UPR and protein secretion (Deranieh and Greenberg, 
2009). 
Several recent studies have demonstrated a key role of inositol supply in regulating 
phosphoinositide levels. In D. discoideum, genetic ablation of the INO1 gene permitted an 
analysis of the effects of inositol depletion on phosphoinositide levels, since all inositol is then 
provided through media supplementation (Frej et al., 2016) (Figure 2). Starving these cells of 
inositol for 24 hours reduced the intracellular level of myo-inositol by 40% (Frej et al., 2016). 
Analysis of phosphoinositides in this model included the differentiation of the two distinct types 
of phosphoinositide, where the predominant type contains an ether linkage of the fatty acids 
to glycerol in D. discoideum and other lower organisms, whereas the predominant species in 
animals contains a diacyl linkage (Clark et al., 2014). Inositol depletion in D. discoideum ino1- 
cells led to a rapid reduction of PI and PIP levels and this was true for both diacyl and ether 
species. Interestingly, diacyl-PIP2 also decreased, but the ether-PIP2 remained unchanged, 
which suggests that the diacyl-PIP2 found in animals is a more labile form of PIP2 than the 
evolutionarily older ether-PIP2 (Frej et al., 2016). In addition, loss of the INO1 protein reduced 
ether-PIP3 levels for all inositol supplementation regimes. Finally, inositol depletion caused a 
rapid (12h) reduction in phosphatidylserine, but did not significantly change other 
glycerophospholipids like phosphatidylethanolamine or phosphatidylcholine. In yeast, inositol 
depletion also modifies total lipid content, including causing a decrease in PI and an increase 
in phosphatidylserine (Yamagami et al., 2015). These data suggest that decreasing inositol 
levels may cause a profound change in cellular phosphatidylinositol signalling. 
Alteration of the levels of phosphoinositides through inositol depletion may have major effects 
on cellular function. For example, PIP2 is an important phospholipid component of cell 
membranes and is a substrate for a number of signalling proteins that regulate the function of 
many membrane proteins and ion channels (Ho et al., 2012). PIP2 has a critical role in 
cytokinesis (Abe et al., 2012), vesicle formation and transport (Klopfenstein et al., 2002), and 
membrane traffic at synapses in the brain (Cremona and De Camilli, 2001). PIP2 is also 
involved in neurotransmitter secretion, nucleation of clathrin coats and the formation of a 
cytoskeletal scaffold to promote endocytosis at the synapse, where PIP2 dephosphorylation 
accompanies the release of newly formed vesicles (Cremona and De Camilli, 2001). Studies 
in yeast have provided further support for the importance of inositol for PIP2 homeostasis: 
removal of INO1 activity that causes inositol depletion triggers altered vacuolar structure and 
decreased vacuolar ATPase activity and proton pumping in isolated vacuolar vesicles 
(Deranieh et al., 2015). The V-ATPase complex couples ATP hydrolysis to proton transport 
into intracellular compartments and across the plasma membrane (Stransky et al., 2016) and 
its functions include membrane trafficking, protein processing and degradation, and the 
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coupled transport of small molecules. PIP3 is another example of a phosphoinositide that is 
important for the regulation of the survival, connectivity and synaptic function of the neurons 
in the central nervous system (Waugh, 2015). Thus, inositol depletion, through reducing the 
levels of phosphoinositides such as PIP2 and PIP3, may have wide-ranging effects on cell 
signalling in health and disease. 
Inositol perturbation and disease 
Altered inositol metabolism has been implicated in various human diseases that include 
neuropsychiatric, neurodegenerative and neurological diseases (Croze et al., 2015; Das et al., 
1994; Prieto et al., 2011; Shimon et al., 1998; Teo et al., 2009; Toker et al., 2014; Trushina et 
al., 2012). The role of phosphoinositide metabolic pathways and the enzymes that have been 
implicated in neurological diseases have been comprehensively reviewed elsewhere (Waugh, 
2015). Here, we will focus on bipolar disorder, Alzheimer disease and epilepsy. 
Inositol imbalance and bipolar disorder 
Bipolar disorder is a devastating neuropsychiatric disorder that leads to severe mood swings 
and causes a dramatic reduction in quality of life and a significant increase in the likelihood of 
suicide (Fajutrao et al., 2009). Perhaps the most clearly demonstrated link between alterations 
in inositol levels and disease is in the treatment of bipolar disorder. Clinical studies have also 
shown that 10 out of 15 patients experienced a reduced severity of bipolar disorder when their 
inositol intake was reduced (Shaldubina et al., 2006). Treatment of patients with either of two 
drugs most commonly prescribed for the disease, lithium and valproic acid (VPA), caused 
changes in inositol levels in the frontal and temporal lobes, the cingulate gyrus, and basal 
ganglia (Silverstone et al., 2005). Additionally, a decrease in inositol levels was reported in 
patients with bipolar disorder that were undergoing drug therapy (Davanzo et al., 2001). 
Clinical studies demonstrating a link between inositol depletion and successful treatment of 
bipolar disorder have received support from experiments in multiple model systems, which 
gave rise to the ‘inositol depletion hypothesis’ (Berridge et al., 1989). Initially, lithium was 
shown to reduce InsP3 levels in rat cerebral cortex slices (Kennedy et al., 1989). Lithium and 
VPA were also found to decrease myo-inositol and increase the inositol monophosphate 
concentration in rat brain extract (O’Donnell et al., 2000). Lithium was then shown to act by 
directly inhibiting purified bovine IMPase (Saudek et al., 1996), which suggests that lithium 
treatment reduces both inositol recycling and biosynthesis, leading to a reduction of an 
overactive inositol-dependent signalling pathway in the brain. This effect was then proposed 
as the therapeutic mechanism of action in bipolar disorder treatment (Berridge et al., 1989). 
Subsequent studies using the structurally distinct compound VPA (Terbach and Williams, 
2009) also showed effects similar to that of lithium treatment. In both yeast and D. discoideum, 
lithium and VPA lower intracellular InsP3 levels and elevate INO1 transcription (Eickholt et al., 
2005; Ju and Greenberg, 2003; Vaden et al., 2001; Williams et al., 2002). In cultured primary 
rat sensory neurons, this common inositol-depleting effect was also observed with a third 
bipolar disorder treatment, carbamazepine, and cellular changes were reversed by the 
addition of exogenous inositol, which confirmed inositol depletion as a mechanism of action 
for structurally disparate bipolar disorder treatments (Williams et al., 2002). A mechanism for 
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the effect of VPA on inositol-linked effects was then suggested by studies in yeast, in which 
VPA inhibited INO1 activity in vivo (Ju et al., 2004), and this mechanism has been supported 
in experiments using mouse brain extracts and human frontal cortex (Shaltiel et al., 2004). 
However, the inhibitory effect of VPA was absent against the purified enzyme (Ju et al., 2004), 
which suggests an indirect mechanism of action of VPA-dependent INO1 inhibition.  
Although inositol phosphates have been the main focus for the effects of bipolar disorder 
treatments (relating to the inositol depletion effect) these changes are likely to impact on 
phosphatidylinositol signalling. Studies in D. discoideum have shown that VPA causes an 
acute reduction in phosphoinositides including PIP2 (Xu et al., 2007)(Chang et al., 2014) 
although again the exact mechanism of this effect remains to be established. Lithium also 
suppresses PIP3-mediated signalling in this model and in a human neutrophil cell line during 
chemotaxis (King et al., 2009). In yeast, treatment with VPA also compromised the 
homeostasis of PIP2 and reduced V-ATPase proton transport in inositol-depleted wild-type 
yeast cells (Deranieh et al., 2015). The perturbation of the V-ATPase was proposed to be a 
consequence of the change in the PIP2 dynamics during low inositol conditions (Deranieh et 
al., 2015). Thus these studies, initiated in simple models and translated to mammalian models, 
suggest a link between inositol deregulation and downstream effects on phosphoinositides. 
Regulation of inositol signalling in bipolar disorder further links to calcium homeostasis, 
through InsP3-dependent calcium release (Deranieh and Greenberg, 2009). The free cytosolic 
concentration of calcium is an important regulator of numerous cellular functions, which 
includes neurotransmitter release, activation of ion channels and cell death, and calcium is 
elevated in patients during mania and depression along with a reduction in the activity of the 
Na+/K+-ATPase (NKA) pump (Looney and El-Mallakh, 1997; Warsh et al., 2004). NKA is a 
membrane-bound enzyme that is abundant in brain tissue and has been linked to bipolar 
disorder pathophysiology and NKA-dependent signal transduction pathways are dependent 
on calcium. Interestingly, lithium and VPA treatment reduce behavioural abnormalities 
associated with mania in the heterozygous Myshkin mouse (Myk-/+) that has an inactive 
neuron-specific α3 isoform of NKA (ATP1A3) (Kirshenbaum et al., 2011). Despite its efficacy, 
lithium has a narrow therapeutic window and a number of unwanted side effects (McKnight et 
al., 2012) and this has triggered a search for alternative treatments that act through a common 
mechanism. Ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one) provides one such 
compound, a seleno-organic drug with anti-inflammatory, anti-atherosclerotic and 
cytoprotective properties (Schewe, 1995) that functions as a lithium mimetic and has been 
tested in phase 1 clinical trials (Singh et al., 2016). Ebselen inhibits IMPase in the human 
brain, therefore reducing inositol levels and thus affecting the phosphoinositide cycle (Masaki 
et al., 2016), which makes it a promising treatment for bipolar disorder and other 
neurodegenerative diseases. 
Inositol imbalance and Alzheimer disease  
Inositol imbalance has also been linked to a range of neurodegenerative diseases including 
Alzheimer disease (AD), which is the most common form of dementia that presently affects 
an estimated 46.8 million people worldwide (Alzheimer’s Disease International, 2015). Indeed, 
the activity and levels of the INO1 enzyme were found to be higher in the post-mortem brains 
of patients with Alzheimer disease (Shimon et al., 1998) and who also show an increased level 
of brain myo-inositol compared to healthy individuals (Griffith et al., 2008). Lithium has also 
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been shown to improve behavioural and cognitive deficits in Alzheimer disease and other 
neurodegenerative disease models that include lateral sclerosis, fragile X syndrome, 
Huntington, and Parkinson diseases (Chiu and Chuang, 2011) and VPA has shown efficacy 
in animal models of Alzheimer disease (Qing et al., 2008). The pathology of AD involves an 
accumulation of amyloid-β (Aβ) peptides into plaques, and the formation of neurofibrillary 
tangles, leading to neuronal cell death in brain regions associated with learning and memory, 
especially in the cortex and the hippocampus (Pereira et al., 2004). Scyllo-inositol and myo-
inositol, two naturally occurring stereoisomers of inositol, inhibit Aβ production and plaque 
accumulation in the brain of a transgenic mouse model of Alzheimer disease that 
demonstrates age-associated cognitive deficits and AD-like pathology (Fenili et al., 2007). 
Scyllo-inositol has also been shown to reverse memory deficits in these mice (McLaurin et al., 
2006).  
Alzheimer disease pathology has been linked to dysregulation of energy metabolism and this 
is critically linked to inositol regulation. The brain has high energy requirements and relies on 
a supply of glucose and oxygen to allow for neurotransmitter production and recycling, 
vesicular trafficking and maintenance of ion gradients for the propagation of action potentials 
and memory. For this purpose, the brain uses about 20% of the oxygen and 25% of the 
glucose consumed by the human body (Be´langer et al., 2011). Energy metabolism has been 
previously associated with inositol regulation in which a generation of S. cerevisiae glycolytic 
mutants (lacking triose phosphate isomerase 1 (Tpi1) and phosphoglycerate kinase 1 (Pgk1)) 
caused an accumulation of dihydroxyacetone phosphate (DHAP) that was inhibitory to INO1 
and led to inositol auxotrophy (Shi et al., 2005). Additionally, the carbohydrate metabolites 
glyceraldehyde 3-phosphate (G3P) and oxaloacetate (OAA) inhibit the activity of human and 
yeast INO1 proteins in vitro (Shi et al., 2005). Inositol and glucose imbalance therefore has a 
major impact on brain energy consumption.  
Metabolomic studies have also shown that a range of fundamental changes occur during 
Alzheimer disease progression. These changes include elevated protein degradation, glucose 
breakdown and pyruvate oxidation (Hoyer, 1990), increased levels of some amino acids, 
serotonin and catecholamine metabolites and alterations in purine metabolic pathways 
(Hoyer, 1990; Kaddurah-Daouk et al., 2013). A link between these changes and inositol has 
recently been suggested through studies in D. discoideum, in which the loss of INO1 (rather 
than inositol depletion per se) caused a shift to catabolic metabolism that was marked by an 
increase in some amino acids, products of nucleoside breakdown and an accumulation of 
Krebs cycle metabolites (Frej et al., 2016). Thus, further studies are necessary to investigate 
if the levels of both inositol and INO1 may modulate the regulation of metabolism in brains of 
Alzheimer disease patients.  
Inositol, phosphoinositides and epilepsy 
Epilepsy is a severe neurological disorder in which patients exhibit repeated seizures and this 
can have a devastating effect on quality of life. Epilepsy is estimated to affect around 50 million 
people worldwide (WHO, 2012) and current treatments do not control seizures in 30% of 
patients (Kwan, 2004). A series of recent papers have demonstrated a role for altered inositol 
and phosphoinositides in seizure activity and as a target for epilepsy treatments. 
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Inositol levels and seizure have been recently linked in a range of studies. Inositol pre-
treatment has been shown to reduce the induction of seizures in multiple models (Belmaker 
and Bersudsky, 2007; Kotaria et al., 2013; Nozadze et al., 2011; Solomonia et al., 2007), and 
seizure activity increases Na+/myo-inositol co-transporter levels (Nonaka et al., 1999; 
Solomonia et al., 2013, 2010). Elevated inositol levels are also found in brain regions that are 
involved in seizure occurrence (Wellard et al., 2003). In a recent study, induction of 
spontaneous seizures showed an initial 20% increase in hippocampal inositol levels (Pascente 
et al., 2016), suggesting a seizure-induced change in inositol signalling in the brain (Y. Wu et 
al., 2015). This elevated level was then shown to persist in animals that went on to develop 
epilepsy (i.e. repeated seizures), but did not persist in animals that did not develop epilepsy. 
These data suggest an association between long-term elevated inositol levels and the 
development of epilepsy, strongly supporting a role for inositol levels in controlling seizures 
and with seizure activity altering these levels.  
Recent studies have also suggested a role for phosphoinositides in seizure activity (Figure 
3). Studies in D. discoideum have shown that VPA and components of the medium chain 
triglyceride (MCT) ketogenic diet act through regulation of phosphoinositides (Chang et al., 
2012; Xu et al., 2007). These studies have then been translated into in vitro and in vivo animal 
models of epilepsy to show that seizure activity decreases brain PIP3 levels and that VPA acts 
to protect against this reduction (Chang et al., 2014). The studies also show that novel 
compounds identified in D. discoideum provide potent seizure control (Chang et al., 2015a, 
2015b, 2013, 2012). The breadth of functions regulated by phosphoinositides that relate to 
seizures and epilepsy make it difficult to identify a single mechanism of action for these 
compounds in seizures. PIP3 provides a key phosphoinositide in a wide variety of cellular 
functions (Vanhaesebroeck et al., 2012) and has many activities that relate to potential seizure 
roles such as voltage-gated channel regulation (Viard et al., 2004), regulation of neuronal 
excitability (MacGregor et al., 2002) and the insertion of ion channels into synaptic plasma 
membranes  (Lhuillier and Dryer, 2002). In addition, PIP2 also regulates epilepsy-related ion 
channel activity (Alberdi et al., 2015) and a recent study of a severe form of epilepsy (DOORS 
syndrome) has identified a causative mutation in the Rab GTPase-activating protein TBC1D24 
that alters a PIP2/PIP3 binding pocket; the synaptic defects that result are reversed by 
elevating PIP2 levels (Fischer et al., 2016). These studies therefore highlight a major role of 
phosphoinositides in seizure activity and protection against changes in phosphoinositide 
levels as a potential therapeutic drug action.  
Autophagy in neurodegenerative diseases 
Autophagy is a process by which the degradation and recycling of cellular material provides 
essential molecules and energy for continued cell function, or to fulfil a protective role by 
clearing damaged and dysfunctional cellular components (Otto et al., 2003). It is triggered by 
cell stress, cellular differentiation and under some developmental conditions. Under stress 
conditions like inflammation, autophagy degrades unwanted proteins however the aberrant 
activation of autophagy may also cause cell death (Kosta et al., 2004). The most common 
form of autophagy, macroautophagy, involves the transport of cytosolic components and 
entire organelles to the lysosomal compartment via specific double-membrane vesicles, called 
autophagosomes. It is a process tightly regulated by the activity of the nutrient-sensing target 
of rapamycin (mTOR) protein kinase, the energy-sensing AMP-activated protein kinase 
(AMPK) and over 30 autophagy-related (ATG) proteins (Alers et al., 2012). AMPK is activated 
under low-energy conditions, leading to autophagy induction, whereas under normal 
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physiological conditions (high energy levels, amino acids, or growth factors), mTOR inhibits 
the canonical autophagy pathway by hyperphosphorylation of Atg13 in yeast or 
ATG13/ULK1/ULK2 in mammals (Alers et al., 2012). Nutrient depletion, reactive oxygen 
species, and rapamycin treatment result in a rapid dephosphorylation of ATG13, an increase 
in Atg1 kinase activity and an induction of autophagy (Kamada et al., 2000). Autophagosome 
formation starts with ATG1 membrane localisation followed by the nucleation of the forming 
autophagosome. The phagophore is then elongated and ubiquitin-like proteins modulate 
conjugation of ATG8 to phosphatidylethanolamine (PE) and assembly of an ATG12/ATG5 in 
the autophagosome membrane (Mizushima et al., 2002). ATG8-PE remains at the membrane, 
and autophagosome maturation continues with elongation, completion, fusion with lysosomes, 
and the degradation and recycling of the sequestered cellular material. These processes are 
controlled by the dynamic regulation of inositol phosphates and phosphoinositides and their 
binding partners (Lystad and Simonsen, 2016) (Vicencio et al., 2009). Mutations in the 
autophagy-related genes have been associated with various human diseases such as 
neurodegenerative diseases, infectious diseases and cancers (Jiang and Mizushima, 2014). 
Autophagy and bipolar disorder 
Autophagy has been suggested to be involved in bipolar disorder since the three structurally 
distinct bipolar disorder drugs carbamazepine, VPA and lithium all induce autophagy via 
inositol depletion in several mammalian cell lines (Sarkar et al., 2005). Lithium reduces InsP3 
levels and induces autophagy, resulting in the clearance of aggregates of proteins (Sarkar et 
al., 2005). This lithium effect is not mediated by a second lithium target, glycogen synthase 
kinase 3 (GSK3β), but by IMPase inhibition since a specific inhibitor (L-690,330) causes 
similar effects. Furthermore, elevating InsP3 reduces lithium-induced clearance of protein 
aggregates and inositol inhibits the degradation of autophagy substrates (Sarkar et al., 2005). 
An inositol depletion-triggered effect of carbamazepine and VPA also induces autophagy 
leading to the killing of mycobacteria within primary human monocyte-derived and alveolar 
macrophages and this process is independent of the mTOR pathway known to regulate 
autophagy (Ghavami et al., 2014), which suggests that inositol depletion may control 
autophagy via a novel myo-inositol-dependent activation pathway (Schiebler et al., 2015). 
Autophagy and Alzheimer disease 
Autophagy has been widely implicated in the progression of Alzheimer disease. In a mouse 
model of Alzheimer disease, the accumulation of autophagosomes in neurons promotes the 
production of Aβ peptides and is accelerated by the overproduction of SUMO1 (Cho et al., 
2015). Depleting several autophagy proteins (ATG5, ATG7 and ATG12) halts the SUMO1-
mediated Aβ production, supporting a role for autophagosome contribution to Aβ production 
and disease pathogenesis (Cho et al., 2015). The accumulation of waste proteins and toxic 
aggregates in the brains of patients with Alzheimer disease could also be a result of the 
dysregulation of autophagy. One possible cause for the accumulation of autophagosomes is 
an inhibition of the fusion of autophagosome with lysosomes (to give autolysosomes). It is 
likely that although SUMO1 increases the autophagic flux, autolysosome formation process is 
defective, thus promoting autophagosome accumulation instead of the degradation of waste 
proteins. This is supported by the finding that SUMO1-overexpressing cells have a higher 
autophagosome to autolysosome ratio than cells treated with trehalose, which induces 
autophagy (Cho et al., 2015). Triggering autophagy by depleting inositol may allow for 
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autolysosome formation to complete and result in the clearance of accumulated dysfunctional 
proteins. Furthermore, inositol polyphosphate-5-phosphatase E (INPP5E), which hydrolyses 
InsP3 and PIP2, is a positive regulator of autophagy (Hasegawa et al., 2016). PIP2 has been 
shown to counteract cortactin-mediated actin filament stabilization on lysosomes to allow for 
their fusion with autophagosomes. Both an excess or depletion of PIP2 on lysosomes have 
been reported to inhibit autophagy during autolysosome formation and lysosomal degradation, 
which suggests that an optimal level of lysosomal PIP2 is essential for autophagy (Hasegawa 
et al., 2016). Since inositol is a precursor of PIP2, changes in inositol levels can have an impact 
on the later stages of autophagy. Inositol depletion can thus have a therapeutic value as a 
regulator of autophagy and sumoylation in the pathogenesis of Alzheimer’s disease. 
Autophagy and epilepsy 
Impaired autophagy has been proposed to contribute to epileptogenesis, through the mTOR 
pathway, that plays a role in neuronal development and the proper functioning of mature 
neurons. Dysregulation of mTOR activity is often observed in a number of neurological 
diseases (Ghavami et al., 2014). Hyperactivation of mTOR has been associated with the 
development of temporal lobe epilepsy (TLE) in humans and in animal models (Buckmaster 
et al., 2009; Hartman et al., 2012; Macias et al., 2013; Sha et al., 2012; Zeng et al., 2009), 
though it is not known which specific processes involved in the generation of epileptic seizures 
require mTOR activity. The mTOR inhibitor rapamycin moderates spontaneous seizure 
development in animal TLE models (Drion et al., 2016; van Vliet et al., 2012; Zeng et al., 
2009), corroborating the epileptogenic effects of mTOR dysfunction. Furthermore, mice 
lacking Atg7, a key protein for autophagy initiation, develop spontaneous seizures (McMahon 
et al., 2012). Autophagy thus may be of interest as a potential therapeutic target for epilepsy 
treatment and/or prevention. A number of anti-epileptic drugs VPA, carbamazepine, 
vigabatrin, acetazolamide, clonazepam, lamotrigine, and levetiracetam have been indeed 
demonstrated to affect autophagy (Cataldi et al., 2005; Fu et al., 2010; Mohammadpour et al., 
2014; Puls et al., 2013; Schiebler et al., 2015; Vogel et al., 2016; Watanabe et al., 2010; H. 
Wu et al., 2015).  
Inositol depletion and decrease in the InsP3 levels has been shown to stimulate autophagy (by 
an mTOR-independent pathway) (Vicencio et al., 2009) while increasing InsP3 levels has been 
demonstrated to inhibit autophagy induced by nutrient depletion (Criollo et al., 2007). This is 
likely related to the role of the InsP3 receptor (InsP3R), as either promoting or suppressing 
autophagy, depending on cellular conditions (Vicencio et al., 2009). The InsP3R is the main 
intracellular calcium release channel governing calcium efflux from the endoplasmic reticulum 
into the cytosol (Vicencio et al., 2009). Under stress conditions Beclin 1 can interact with 
InsP3R leading to an increased Ca2+ release, which can diffuse into cytosol to stimulate the 
induction of autophagy (Vicencio et al., 2009). Also, Levetiracetam has been reported to 
reduce the InsP3-dependent calcium release initiated by a Gq-coupled receptor activation (a 
process that plays a role in triggering and maintaining seizures) in rat PC12 cells at 
concentrations that are in the range observed in the plasma of patients treated with the drug 




In conclusion, inositol homeostasis is regulated by uptake, biosynthesis and recycling 
mechanisms. Inositol is vital for maintaining proper cell function and inositol depletion triggers 
molecular changes that can eventually lead to a disease state. A series of recent studies in 
simple model systems has shown that a reduction of inositol levels is likely to causes changes 
in both inositol phosphate and phosphatidylinositol signalling that widely impacts on numerous 
cellular functions including transcription, metabolism, ion channel and synaptic function, 
calcium homeostasis, and energy metabolism, and to directly impact on autophagy. Through 
these numerous mechanisms, dysregulated inositol levels are likely to play an important part 
in a range of neurological diseases that include bipolar disorder, Alzheimer disease and 
epilepsy.  
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Figure 1. The structure of inositol and its derivatives, and inositol-dependent signalling. 
A. Inositol is a polyalcohol that comprises a six ring carbon with hydroxyl groups on each 
carbon and provides a key part of two families of chemicals. B. The first family is 
phosphoinositides, which includes phosphoinositol, and comprises an inositol head group 
(green) that is linked via a phosphate group to a glycerol backbone with two attached fatty 
acids. Two species of phosphoinositide are found, where the linkage to one fatty acid is 
through either an ether or an acyl group. C. The second family is inositol phosphates such as 
inositol trisphosphate, in which the inositol group is phosphorylated at defined carbons (e.g. 
positions 1, 4 and 5). D. Key phosphoinositides include PIP2 (shown) or PIP3, in which the 
inositol head group of the phosphoinositide is phosphorylated on defined carbons (e.g. 
position 4 and 5). E. Inositol can enter cells through Na+–myo-inositol transporters (SMITs) 
and the H+–myo-inositol transporter (HMIT). Inositol and diacylglycerol (DAG) then provide a 
variety of phosphoinositides including phosphatidylinositol (PI), phosphatidylinositol 
phosphate (PIP) and phosphatidylinositol bisphosphate (PIP2), which can then be further 
phosphorylated by the phosphatidylinositol bisphosphate 3-kinase (PI3K) protein family to 
form phosphatidylinositol trisphosphate (PIP3), or degraded by phospholipase C (PLC) activity 
to form inositol phosphates that include inositol trisphosphate (InsP3). InsP3 can also be 
formed by the dephosphorylation of higher order inositol phosphates (InsP4, InsP5, InsP6), 
which is catalysed by multiple inositol-polyphosphate phosphatase (MIPP). InsP3 is broken 
down by sequential removal of the phosphate groups by inositol polyphosphate phosphatase 
(IPP) to form inositol bisphosphate (InsP2) and inositol monophosphate (InsP1) and by inositol 
monophosphatase (IMPase) to form inositol. Inositol may also be produced through de novo 







Figure 3. The social amoeba Dictyostelium discoideum has been used to investigate 
the role of inositol, inositol phosphates and phosphoinositides. A. The gene encoding 
for the INO1 protein in Dictyostelium has been removed and INO1 is not produced in ino1- 
cells. B. Compared to wild-type vegetative cells (left), the ino1- cells starved of inositol for 30 
hours (right) are visibly more rounded. C. Dictyostelium cells that cannot produce INO1 require 
inositol supplementation in order to proliferate. Restoring INO1 production in these cells (ino1-
::ino1–RFP) rescues the growth of the ino1- mutant cells in the absence of inositol. D. Inositol 
is required for development in Dictyostelium. Ino1- mutant cells are not able to develop without 
inositol treatment. Restoring INO1 production in these cells (ino1-::ino1–RFP) rescues the 
development of the ino1- mutant cells in the absence of inositol. Since the inositol auxotrophic 
ino1- mutant is able to grow and develop when supplied with exogenous inositol, these mutant 
























Figure 4. New treatments for epilepsy that were identified in Dictyostelium discoideum, 
which regulate phosphoinositide signalling and show efficacy in seizure models. A. 
Through the analysis of the mechanism of action of valproic acid (VPA), a range of related 
chemicals that include decanoic acid (DA), nonanoic acid (NA), 4-methyloctanoic acid (4-MO) 
and 4-ethyloctanoic acid (4-EO) were identified. B. These compounds show strong seizure 
control in a generalised seizure model in which seizure-like activity is induced in a rat 
hippocampal slice and is controlled by the addition of compounds (from Chang et al, 2012, 
2016).  
 
 
 
